Entity

Time filter

Source Type


Montes-Moreno S.,Lymphoma Group | Gonzalez-Medina A.-R.,Hospital General de Segovia | Rodriguez-Pinilla S.-M.,Lymphoma Group | Maestre L.,Monoclonal Antibodies Unit | And 9 more authors.
Haematologica | Year: 2010

Background Plasmablastic lymphoma has recently come to be considered a distinct entity among mature B cell neoplasms, although the limits with diffuse large B-cell lymphoma (DLBCL) need to be more accurately defined. Design and Methods Here we show the results of an immunohistochemical study of 35 cases of plasmablastic lymphoma compared with a set of 111 conventional DLBCLs. Results Our results demonstrate that the use of a limited combination of immunohistochemical markers (PAX5&CD20, PRDM1/BLIMP1 and XBP1s) enables the identification of a plasmablastic immunophenotype highly characteristic of plasmablastic lymphoma cases and associated with an aggressive clinical behavior. Additionally, the study shows that the acquisition of a partial plasmablastic phenotype (PRDM1/BLIMP1 expression) in DLBCL is associated with shorter survival in R-CHOP-treated patients. Conclusions The use of a restricted combination of immunohistochemical markers (PAX5&CD20, PRDM1/BLIMP1 and XBP1s) enables a more accurate definition of terminal differentiation for large B-cell lymphoma. © 2010 Ferrata Storti Foundation. Source


Molina-Garrido M.J.,Consulta de Cancer en el Anciano | Guillen-Ponce C.,Hospital General Universitario Ramon y Cajal | Mora-Rufete A.,Hospital General Universitario Of Elche
Anti-Cancer Agents in Medicinal Chemistry | Year: 2014

Trastuzumab or lapatinib treatment with chemotherapy or hormonotherapy are the gold standard treatments for human epidermal growth factor receptor 2 (HER2)-positive breast cancer (early breast cancer or metastatic breast cancer). Older patients have been largely underrepresented in clinical trials, and few data on trastuzumab or lapatinib efficacy and toxicity have been reported for this subgroup. This article has reviewed the main articles that have analyzed these items. © 2014 Bentham Science Publishers. Source


Molina-Garrido M.J.,Consulta de Cancer en el Anciano | Molina-Garrido M.J.,Hospital General Universitario Ramon y Cajal | Mora-Rufete A.,Hospital General Universitario Of Elche | Mora-Rufete A.,Hospital General Universitario Ramon y Cajal | And 2 more authors.
Anti-Cancer Agents in Medicinal Chemistry | Year: 2014

Life expectancy has significantly increased over the past 30 years, with a greater prevalence of diverse disease states, especially cancer. As older persons are a very heterogeneous group with an increased prevalence of comorbidities and a relative inability to tolerate the adverse effects of chemotherapy, the treatment of cancer in the elderly is particularly demanding. The principles of its management are similar to those in younger patients but with special considerations linked to comorbidities and clinical status. The objective of chemotherapeutic treatment in metastatic breast cancer has historically been primarily palliative. The introduction of newer approaches with improved or at least equivalent efficacy and reduced toxicity is highly desirable. Such approaches may include the use of less toxic drugs, more convenient routes of administration (e.g., oral) and home-based (outpatient) rather than hospital-based therapies. The available oral cytostatic drugs include vinorelbine and capecitabine. In this review, we analyze oral cytostatic drugs in the elderly patient diagnosed with metastatic breast cancer. © 2014 Bentham Science Publishers. Source

Discover hidden collaborations